SUBSCRIBE
SUBSCRIBE
News   Deals

GlaxoSmithKline Has No Genzyme Corporation Interest, Seeks Lower R&D Risk

November 19, 2010 | 
1 min read
BOSTON (Reuters) - GlaxoSmithKline Plc says it is not interested in making a counterbid for U.S. biotech company Genzyme Corp and that an acquisition of such size would be disruptive to its own research and development.
Mergers & acquisitions
GSK
MORE ON THIS TOPIC
Investment mistakes, taxes, expenses, and unknown costs drain money, concept of Businessman carries a money bag with a big hole, banknotes falling out
Funding
Recordati fields $12.4B go-private offer
May 22, 2026
 · 
2 min read
 · 
Tristan Manalac
High Quality background with Two Flags of South Korea and USA
Manufacturing
Gilead inks $140M API supply deal, tightening ties to Korean manufacturer
May 22, 2026
 · 
1 min read
 · 
Nick Paul Taylor
too many different pill of various blisters with different pills Medicines storage at home concept Medication storing. A pile of medicine in blister packs. Pharmaceutical blister packs.
Manufacturing
Roche licensing pact clears generic drugmakers to manufacture antiviral flu drug
May 21, 2026
 · 
2 min read
 · 
Nick Paul Taylor
A human hand and a robot hand shake hands over a white circle on a green background
Artificial intelligence
Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling
May 21, 2026
 · 
3 min read
 · 
Tristan Manalac